Outpatient Treatment of Chlamydophila pneumoniae Pneumonia in Adults Without Comorbidities
This protocol addresses adults with community-acquired pneumonia managed entirely in the outpatient setting who have no underlying chronic conditions and no risk factors for infection with antibiotic-resistant organisms.
Clinical Scenario
Adult treated as an outpatient for community-acquired pneumonia. No chronic heart, lung, liver, or renal disease; no diabetes mellitus, alcoholism, malignancy, or asplenia. No prior respiratory isolation of MRSA or P. aeruginosa, and no recent hospitalization with receipt of parenteral antibiotics in the last 90 days.
Treatment Approach
Oral antibiotic monotherapy is recommended for this population. The appropriate agent class depends in part on local resistance patterns.
The complete regimen — specific agent options, selection criteria, and duration guidance — is available in the full protocol below.
Treatment Goal
Achievement of clinical stability: resolution of vital sign abnormalities (heart rate, respiratory rate, blood pressure, oxygen saturation, and temperature), ability to eat, and normal mentation. Most patients reach stability within 48 to 72 hours; therapy should continue for no less than a total of 5 days.
References
DOI: 10.1164/rccm.201908-1581ST
- For healthy outpatient adults without comorbidities listed below or risk factors for antibiotic resistant pathogens, we recommend (Table 3):
- Comorbidities include chronic heart, lung, liver, or renal disease; diabetes mellitus; alcoholism; malignancy; or asplenia.
- Risk factors include prior respiratory isolation of MRSA or P. aeruginosa or recent hospitalization AND receipt of parenteral antibiotics (in the last 90 d).
- amoxicillin 1 g three times daily (strong recommendation, moderate quality of evidence), or
- doxycycline 100 mg twice daily (conditional recommendation, low quality of evidence), or
- a macrolide (azithromycin 500 mg on first day then 250 mg daily or clarithromycin 500 mg twice daily or clarithromycin extended release 1,000 mg daily) only in areas with pneumococcal resistance to macrolides <25% (conditional recommendation, moderate quality of evidence).
- We recommend that the duration of antibiotic therapy should be guided by a validated measure of clinical stability (resolution of vital sign abnormalities [heart rate, respiratory rate, blood pressure, oxygen saturation, and temperature], ability to eat, and normal mentation), and antibiotic therapy should be continued until the patient achieves stability and for no less than a total of 5 days (strong recommendation, moderate quality of evidence).
- As most patients will achieve clinical stability within the first 48 to 72 hours, a total duration of therapy of 5 days will be appropriate for most patients.
View source ↗